Developer docs
API playgroundTry for free, no card

Search company profiles

Catheter Precision

Full company profile

uuid0002x5s

Namestring
Catheter Precision
Legal namestring
Catheter Precision Inc.
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Catheter Precision, Inc. (NYSE American: VTAK) is a US-domiciled, publicly traded medical device company that develops and markets products for cardiac electrophysiology procedures. The company's core medical products are VIVO, a non-invasive 3D cardiac imaging system that uses proprietary inverse-solution algorithms applied to 12-lead ECG and CT/MRI inputs to localize ventricular arrhythmias pre-procedure (with 99.5% accuracy and 27% shorter procedure times in clinical data), and LockeT, a suture retention device for vascular access site closure that achieves 98% hemostasis at 2 hours in clinical studies and enables same-day discharge for catheter sizes up to 27F. Both products hold FDA clearance, and LockeT additionally carries the CE Mark for European sale. The company sells primarily to hospitals and electrophysiology labs through direct sales teams and regional distributors such as FuMedica AG in Switzerland, with named customers including Mater Private Hospital (Ireland), Spitalzentrum Biel (Switzerland), and five South African hospitals.

In March 2026 Catheter Precision completed the acquisition of the remaining 80.02% of Fly Flyte, Inc., giving it 100% ownership of Flyte, an AI-enabled regional air mobility operator running Cirrus Vision Jets under FAA Part 135 certification through subsidiary Ponderosa Air, LLC. Flyte operates short-haul routes along the US East Coast (Maine to Florida following the March 2026 Florida expansion) and has joined the Vaunt operator network to monetize repositioning flights. Revenue streams consist of hardware sales of VIVO and LockeT devices, royalty income from the February 2026 divestiture of atherectomy catheter technologies (1.5%-3% of net sales for ten years plus a 5% equity stake in the acquirer), and aviation charter revenue, with Q1 2026 consolidated revenue of $432,000 (up 200% year-over-year) and a Q1 2026 net loss of $1.7M (improved from $4.0M a year earlier).

The company is undergoing a strategic pivot: in April 2026 management announced it is actively seeking a buyer for the cardiac electrophysiology business in order to focus on the Flyte aviation platform, while concurrently strengthening the balance sheet via up to $36.5M of strategic institutional financing (February 2026), expanding the IP portfolio with 11 newly allowed patents (June 2026), and taking a 7.5% strategic stake in Volato Group, Inc. to align with the Parslee / Volato AI aviation software ecosystem. Catheter Precision is led by founder-CEO David Jenkins (former CEO of EP MedSystems and Arrhythmia Research Technology) and CFO Phil Anderson, and is headquartered in Fort Mill, South Carolina, with an EU authorized representative in Münster, Germany.

Short descriptiontext

Catheter Precision (NYSE American: VTAK) develops FDA-cleared cardiac electrophysiology devices, including the VIVO non-invasive 3D cardiac imaging system and LockeT suture retention device, and operates Flyte, an AI-enabled regional air mobility subsidiary using Cirrus Vision Jets under FAA Part 135 certification.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFort Mill, United States
HQ citystring
Fort Mill
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac electrophysiology devices, 3D cardiac imaging, vascular closure devices, regional air mobility, arrhythmia localization
Industry2 codes
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Electrophysiology Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

Revenue from sales of LockeT suture retention devices and VIVO imaging systems to hospitals and electrophysiology labs in the US and internationally (Europe, South Africa, Switzerland, Ireland). Q1 2026 revenue of $432,000 representing 200% year-over-year growth.

stocktitan.net
2Royalty Income
TypeLicensing Royalties
Description

Ten-year royalty payments of 1.5% to 3% on net sales from the divestiture of atherectomy catheter technologies, plus 5% equity stake in acquiring company with anti-dilution protection.

benzinga.com
3Aviation Services
TypeTransaction Fee
Description

Revenue from Flyte's regional air mobility platform operating Cirrus Vision Jets on short-haul routes. Flyte achieved $200,000 monthly revenue run rate within 22 days of post-acquisition operations in March 2026. Soft launch in Florida generated over $160,000 in inbound flight bookings on a single aircraft.

nasdaq.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
Pricing details1 tier
1Direct sales to hospitals and distributors
ModelOtherBilling cadenceMulti-year contract
Notes

Products sold directly to hospitals through sales team and through international distributors. Pricing determined through hospital procurement processes.

catheterprecision.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1VIVO
Description

Non-invasive 3D cardiac imaging system for pre-procedure arrhythmia localization

catheterprecision.com
+3 more records
Core offering1 text field

Catheter Precision develops, manufactures, and markets medical devices for cardiac electrophysiology procedures, including the VIVO non-invasive 3D cardiac imaging system for pre-procedure arrhythmia localization and the LockeT suture retention device for vascular closure after catheter procedures. Through its wholly owned Flyte subsidiary, the company also operates AI-enabled regional air mobility services using Cirrus Vision Jets on East Coast short-haul routes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 27% shorter procedure time with VIVO system
+4 more records
Product overview1 text field

Catheter Precision operates as a dual-engine growth platform combining clinically validated medical devices with technology-enabled aviation infrastructure. The medical device segment centers on two FDA-cleared/CE Marked products: VIVO, a non-invasive 3D cardiac imaging system using proprietary algorithms for pre-procedure arrhythmia localization, and LockeT, a suture retention device for access site closure enabling same-day discharge. The company also operates Flyte, a regional air mobility subsidiary utilizing Cirrus Vision Jets, which was fully acquired in March 2026. The portfolio spans electrophysiology procedures, cardiac imaging, and private aviation services, supported by a library of over 50 patents.

Product and service3 records
1VIVO Non-Invasive 3D Cardiac Imaging System
CategoryCardiac Imaging Systems
Description

Non-invasive 3D cardiac imaging system that uses standard 12-lead ECG recordings combined with CT/MRI imaging and proprietary inverse-solution algorithms to create patient-specific 3D heart models with activation maps for pre-procedure localization of ventricular arrhythmias. For electrophysiology labs and hospitals performing cardiac catheter ablation procedures.

2LockeT Suture Retention Device
CategoryVascular Closure Devices
Description

External compression vascular closure device used with a figure-of-eight suture technique to achieve hemostasis after cardiac catheter access procedures. Compatible with catheter sizes up to 27F and enables same-day hospital discharge with 98% hemostasis success at 2 hours in clinical studies. For hospitals and electrophysiology labs performing catheter-based procedures.

3Flyte Regional Air Mobility Service
CategoryRegional Air Mobility Services
Description

AI-enabled regional air mobility service operating FAA Part 135 certified flights using Cirrus Vision Jets on high-frequency short-haul routes along the U.S. East Coast (Maine to Florida), through wholly owned subsidiary Ponderosa Air, LLC. For high-net-worth individuals, corporate hospitality groups, and professional athletes.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-06-22
Description

Flyte partnered with sports agency GSE Worldwide and PGA TOUR professional Emiliano Grillo, debuting at the 2026 U.S. Open Championship. The partnership showcases Flyte's fleet of Cirrus Vision Jets as a regional travel alternative for professional athletes with demanding multi-market schedules. Positions Flyte for continued expansion into professional sports.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-11
Description

Flyte joined the Vaunt operator network, a membership-based private aviation platform owned by Volato Group, Inc. The partnership allows Flyte's fleet of Cirrus Vision Jets to access Vaunt's expanding member base, creating new opportunities to monetize repositioning flights and increase aircraft utilization. Vaunt reported $3.6M annual recurring revenue with 162% YoY growth.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-08
Description

Flyte (subsidiary of Catheter Precision) acquired approximately 2.9 million shares representing a 7.5% ownership stake in Volato Group, becoming its largest shareholder. The strategic investment aims to explore potential future collaboration across private aviation platforms and create long-term shareholder value for both organizations. Volato operates Parslee AI software platform and is developing Volato AI for aviation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Catheter Precision acquired remaining 80.02% equity interest in Fly Flyte, Inc. from Creatd, Inc., achieving 100% ownership. Transaction valued at approximately $6 million in cash and nearly $6 million in Convertible Preferred Stock. Flyte became wholly owned subsidiary with financial results consolidated into VTAK's statements.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-16
Description

Swiss medical distributor FuMedica AG distributes LockeT suture retention device in Switzerland through partnership agreement. Initial procedures performed at Spitalzentrum Biel. Partnership aims to enhance cardiac procedure outcomes in Swiss hospitals.

6PeriKard, LLC
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-15
Description

Catheter Precision announced a definitive agreement to acquire PeriKard, LLC, expanding its cardiac electrophysiology portfolio.

newswire.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Acutus Medical
TypeDirect peer
Description

Acutus Medical develops cardiac electrophysiology mapping and ablation technologies, directly comparable to Catheter Precision's VIVO imaging system in the ventricular arrhythmia pre-procedure planning category.

TypeBroad incumbent
Description

Boston Scientific is a major incumbent in cardiac electrophysiology through its EP and cardiac surgery franchises, providing direct competition and representing a likely strategic acquirer for Catheter Precision's EP portfolio.

3Abbott
TypeBroad incumbent
Description

Abbott competes in both cardiac EP (mapping/ablation) and vascular closure (Perclose, StarClose), making it directly comparable across Catheter Precision's two medical device product lines and a potential strategic acquirer.

4Biosense Webster (Johnson & Johnson)
TypeBroad incumbent
Description

Biosense Webster is the dominant incumbent in cardiac electrophysiology mapping and ablation (CARTO 3D system), making it the most significant competitor to VIVO in pre-procedure arrhythmia localization.

5Haemonetics
TypeDirect peer
Description

Haemonetics' Vascade vascular closure device directly competes with LockeT in the post-catheter access site closure market for both electrophysiology and interventional cardiology procedures.

TypeBroad incumbent
Description

Terumo's Angio-Seal is one of the leading vascular closure devices globally, competing with LockeT across catheter-based procedures in hospitals and electrophysiology labs.

TypeBroad incumbent
Description

Medtronic is a broad incumbent in cardiac diagnostics, EP, and structural heart, with cardiac diagnostic and monitoring capabilities that overlap with VIVO's pre-procedure imaging franchise.

TypeEmerging player
Description

CathVision is an emerging player in cardiac EP signal acquisition and mapping technology, comparable to VIVO as an innovation-driven EP imaging player targeting the same electrophysiology lab customers.

TypeDirect peer
Description

Volato operates the Vaunt membership-based private aviation platform and is both a strategic partner (7.5% Catheter Precision stake) and a directly comparable regional private aviation operator using similar aircraft classes.

TypeBroad incumbent
Description

Wheels Up is an established private aviation membership platform operating regional and national routes, comparable to Flyte's positioning in short-haul, high-frequency regional private aviation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Catheter Precision

Cardiac Electrophysiology Medical Devicescatheterprecision.com

Catheter Precision (NYSE American: VTAK) develops FDA-cleared cardiac electrophysiology devices, including the VIVO non-invasive 3D cardiac imaging system and LockeT suture retention device, and operates Flyte, an AI-enabled regional air mobility subsidiary using Cirrus Vision Jets under FAA Part 135 certification.

What Catheter Precision does

Catheter Precision, Inc. (NYSE American: VTAK) is a US-domiciled, publicly traded medical device company that develops and markets products for cardiac electrophysiology procedures. The company's core medical products are VIVO, a non-invasive 3D cardiac imaging system that uses proprietary inverse-solution algorithms applied to 12-lead ECG and CT/MRI inputs to localize ventricular arrhythmias pre-procedure (with 99.5% accuracy and 27% shorter procedure times in clinical data), and LockeT, a suture retention device for vascular access site closure that achieves 98% hemostasis at 2 hours in clinical studies and enables same-day discharge for catheter sizes up to 27F. Both products hold FDA clearance, and LockeT additionally carries the CE Mark for European sale. The company sells primarily to hospitals and electrophysiology labs through direct sales teams and regional distributors such as FuMedica AG in Switzerland, with named customers including Mater Private Hospital (Ireland), Spitalzentrum Biel (Switzerland), and five South African hospitals.

In March 2026 Catheter Precision completed the acquisition of the remaining 80.02% of Fly Flyte, Inc., giving it 100% ownership of Flyte, an AI-enabled regional air mobility operator running Cirrus Vision Jets under FAA Part 135 certification through subsidiary Ponderosa Air, LLC. Flyte operates short-haul routes along the US East Coast (Maine to Florida following the March 2026 Florida expansion) and has joined the Vaunt operator network to monetize repositioning flights. Revenue streams consist of hardware sales of VIVO and LockeT devices, royalty income from the February 2026 divestiture of atherectomy catheter technologies (1.5%-3% of net sales for ten years plus a 5% equity stake in the acquirer), and aviation charter revenue, with Q1 2026 consolidated revenue of $432,000 (up 200% year-over-year) and a Q1 2026 net loss of $1.7M (improved from $4.0M a year earlier).

The company is undergoing a strategic pivot: in April 2026 management announced it is actively seeking a buyer for the cardiac electrophysiology business in order to focus on the Flyte aviation platform, while concurrently strengthening the balance sheet via up to $36.5M of strategic institutional financing (February 2026), expanding the IP portfolio with 11 newly allowed patents (June 2026), and taking a 7.5% strategic stake in Volato Group, Inc. to align with the Parslee / Volato AI aviation software ecosystem. Catheter Precision is led by founder-CEO David Jenkins (former CEO of EP MedSystems and Arrhythmia Research Technology) and CFO Phil Anderson, and is headquartered in Fort Mill, South Carolina, with an EU authorized representative in Münster, Germany.

Catheter Precision firmographics

Firmographics
Name
Catheter Precision
Legal name
Catheter Precision Inc.
Website
https://catheterprecision.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Catheter Precision (NYSE American: VTAK) develops FDA-cleared cardiac electrophysiology devices, including the VIVO non-invasive 3D cardiac imaging system and LockeT suture retention device, and operates Flyte, an AI-enabled regional air mobility subsidiary using Cirrus Vision Jets under FAA Part 135 certification.
Ownership category
akta.pro rank

Catheter Precision industry classification

Industry
Product category
Cardiac Electrophysiology Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)

Keywords

  • Cardiac electrophysiology devices
  • 3D cardiac imaging
  • Vascular closure devices
  • Regional air mobility
  • Arrhythmia localization

Where Catheter Precision is headquartered

Location

Headquarters

HQ city
Fort Mill
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Catheter Precision business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Medical Device Sales: Revenue from sales of LockeT suture retention devices and VIVO imaging systems to hospitals and electrophysiology labs in the US and internationally (Europe, South Africa, Switzerland, Ireland). Q1 2026 revenue of $432,000 representing 200% year-over-year growth.
  2. Royalty Income: Ten-year royalty payments of 1.5% to 3% on net sales from the divestiture of atherectomy catheter technologies, plus 5% equity stake in acquiring company with anti-dilution protection.
  3. Aviation Services: Revenue from Flyte's regional air mobility platform operating Cirrus Vision Jets on short-haul routes. Flyte achieved $200,000 monthly revenue run rate within 22 days of post-acquisition operations in March 2026. Soft launch in Florida generated over $160,000 in inbound flight bookings on a single aircraft.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractDirect sales to hospitals and distributors

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Catheter Precision product offering

Product offering

Core offering

Catheter Precision develops, manufactures, and markets medical devices for cardiac electrophysiology procedures, including the VIVO non-invasive 3D cardiac imaging system for pre-procedure arrhythmia localization and the LockeT suture retention device for vascular closure after catheter procedures. Through its wholly owned Flyte subsidiary, the company also operates AI-enabled regional air mobility services using Cirrus Vision Jets on East Coast short-haul routes.

Product overview

Catheter Precision operates as a dual-engine growth platform combining clinically validated medical devices with technology-enabled aviation infrastructure. The medical device segment centers on two FDA-cleared/CE Marked products: VIVO, a non-invasive 3D cardiac imaging system using proprietary algorithms for pre-procedure arrhythmia localization, and LockeT, a suture retention device for access site closure enabling same-day discharge. The company also operates Flyte, a regional air mobility subsidiary utilizing Cirrus Vision Jets, which was fully acquired in March 2026. The portfolio spans electrophysiology procedures, cardiac imaging, and private aviation services, supported by a library of over 50 patents.

Differentiator

Problem solved

Functional benefit

Brands

  • VIVO: Non-invasive 3D cardiac imaging system for pre-procedure arrhythmia localization
  • LockeT
  • Ponderosa Air
  • Flyte

Products and services

  • VIVO Non-Invasive 3D Cardiac Imaging System Non-invasive 3D cardiac imaging system that uses standard 12-lead ECG recordings combined with CT/MRI imaging and proprietary inverse-solution algorithms to create patient-specific 3D heart models with activation maps for pre-procedure localization of ventricular arrhythmias. For electrophysiology labs and hospitals performing cardiac catheter ablation procedures.
  • LockeT Suture Retention Device External compression vascular closure device used with a figure-of-eight suture technique to achieve hemostasis after cardiac catheter access procedures. Compatible with catheter sizes up to 27F and enables same-day hospital discharge with 98% hemostasis success at 2 hours in clinical studies. For hospitals and electrophysiology labs performing catheter-based procedures.
  • Flyte Regional Air Mobility Service AI-enabled regional air mobility service operating FAA Part 135 certified flights using Cirrus Vision Jets on high-frequency short-haul routes along the U.S. East Coast (Maine to Florida), through wholly owned subsidiary Ponderosa Air, LLC. For high-net-worth individuals, corporate hospitality groups, and professional athletes.

Quantifiable outcome

  • 27% shorter procedure time with VIVO system
  • +4 more outcomes

Companies that use Catheter Precision

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Catheter Precision technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Catheter Precision partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • GSE WorldwidecoreGTM or Marketing Partner · 22 June 2026Flyte partnered with sports agency GSE Worldwide and PGA TOUR professional Emiliano Grillo, debuting at the 2026 U.S. Open Championship. The partnership showcases Flyte's fleet of Cirrus Vision Jets as a regional travel alternative for professional athletes with demanding multi-market schedules. Positions Flyte for continued expansion into professional sports.
  • Vaunt (Volato Group)coreChannel Partner/ Reseller/ Distributor · 11 June 2026Flyte joined the Vaunt operator network, a membership-based private aviation platform owned by Volato Group, Inc. The partnership allows Flyte's fleet of Cirrus Vision Jets to access Vaunt's expanding member base, creating new opportunities to monetize repositioning flights and increase aircraft utilization. Vaunt reported $3.6M annual recurring revenue with 162% YoY growth.
  • Volato Group, Inc.coreStrategic or Co-development Partner · 8 June 2026Flyte (subsidiary of Catheter Precision) acquired approximately 2.9 million shares representing a 7.5% ownership stake in Volato Group, becoming its largest shareholder. The strategic investment aims to explore potential future collaboration across private aviation platforms and create long-term shareholder value for both organizations. Volato operates Parslee AI software platform and is developing Volato AI for aviation.
  • Creatd, Inc.coreStrategic or Co-development Partner · 17 February 2026Catheter Precision acquired remaining 80.02% equity interest in Fly Flyte, Inc. from Creatd, Inc., achieving 100% ownership. Transaction valued at approximately $6 million in cash and nearly $6 million in Convertible Preferred Stock. Flyte became wholly owned subsidiary with financial results consolidated into VTAK's statements.
  • FuMedica AGcoreChannel Partner/ Reseller/ Distributor · 16 October 2025Swiss medical distributor FuMedica AG distributes LockeT suture retention device in Switzerland through partnership agreement. Initial procedures performed at Spitalzentrum Biel. Partnership aims to enhance cardiac procedure outcomes in Swiss hospitals.
  • PeriKard, LLCminorStrategic or Co-development Partner · 15 January 2025Catheter Precision announced a definitive agreement to acquire PeriKard, LLC, expanding its cardiac electrophysiology portfolio.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Catheter Precision competitors and assessment

Company assessment

Direct peers

  • Acutus Medical: Acutus Medical develops cardiac electrophysiology mapping and ablation technologies, directly comparable to Catheter Precision's VIVO imaging system in the ventricular arrhythmia pre-procedure planning category.
  • Haemonetics: Haemonetics' Vascade vascular closure device directly competes with LockeT in the post-catheter access site closure market for both electrophysiology and interventional cardiology procedures.
  • Volato Group: Volato operates the Vaunt membership-based private aviation platform and is both a strategic partner (7.5% Catheter Precision stake) and a directly comparable regional private aviation operator using similar aircraft classes.

Broad incumbents

  • Boston Scientific: Boston Scientific is a major incumbent in cardiac electrophysiology through its EP and cardiac surgery franchises, providing direct competition and representing a likely strategic acquirer for Catheter Precision's EP portfolio.
  • Abbott: Abbott competes in both cardiac EP (mapping/ablation) and vascular closure (Perclose, StarClose), making it directly comparable across Catheter Precision's two medical device product lines and a potential strategic acquirer.
  • Biosense Webster (Johnson & Johnson): Biosense Webster is the dominant incumbent in cardiac electrophysiology mapping and ablation (CARTO 3D system), making it the most significant competitor to VIVO in pre-procedure arrhythmia localization.
  • Terumo Medical: Terumo's Angio-Seal is one of the leading vascular closure devices globally, competing with LockeT across catheter-based procedures in hospitals and electrophysiology labs.
  • Medtronic: Medtronic is a broad incumbent in cardiac diagnostics, EP, and structural heart, with cardiac diagnostic and monitoring capabilities that overlap with VIVO's pre-procedure imaging franchise.
  • Wheels Up: Wheels Up is an established private aviation membership platform operating regional and national routes, comparable to Flyte's positioning in short-haul, high-frequency regional private aviation.

Emerging players

  • CathVision: CathVision is an emerging player in cardiac EP signal acquisition and mapping technology, comparable to VIVO as an innovation-driven EP imaging player targeting the same electrophysiology lab customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Catheter Precision social profiles

Digital presence

Catheter Precision compliance and trust

Trust signal

Compliance1 record

Catheter Precision financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Catheter Precision leadership team

Management profile

Number of profiles

Profiles2 records

Catheter Precision subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Catheter Precision funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Catheter Precision M&A and investment

M&A and investment

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Catheter Precision

What does Catheter Precision do?

Catheter Precision develops, manufactures, and markets medical devices for cardiac electrophysiology procedures, including the VIVO non-invasive 3D cardiac imaging system for pre-procedure arrhythmia localization and the LockeT suture retention device for vascular closure after catheter procedures. Through its wholly owned Flyte subsidiary, the company also operates AI-enabled regional air mobility services using Cirrus Vision Jets on East Coast short-haul routes.

Is Catheter Precision a public or private company?

Catheter Precision is a public company. It is classified as public and is currently operating.

When was Catheter Precision founded?

Catheter Precision was founded in 2007. It employs 11 to 50 people.

Where is Catheter Precision based?

Catheter Precision is headquartered in Fort Mill, United States, in the North America region.

How does Catheter Precision make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are royalty Income and aviation Services.

Who are Catheter Precision's main competitors?

Direct peers on record are Acutus Medical, Haemonetics and Volato Group. Broad incumbents are Boston Scientific, Abbott, Biosense Webster (Johnson & Johnson), Terumo Medical, Medtronic and Wheels Up. CathVision is listed as an emerging player.

Does Catheter Precision have an API?

No public API is recorded for Catheter Precision.

What industry is Catheter Precision in?

Catheter Precision's product category is Cardiac Electrophysiology Medical Devices. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewCatheter Precision: Aviation revenue surged 145% sequentially as fleet utilization climbedCatheter Precision reported Q3 aviation revenue of $1.838 million, up 145% sequentially, with flight hours up 129% and over 99% of customer flights handled by the fleet. Three aircraft are expected to enter revenue service in Q4, while a proposed MedTech divestiture remains nonbinding.Stock TitanCatheter Precision completes first VIVO case in GermanyCatheter Precision completed its first commercial VIVO case at Klinikum Bayreuth in Germany, where the system helped identify arrhythmia morphologies and reduce procedure time. The company plans to convert initial Q4 evaluations into recurring commercial adoption, aiming for revenue growth.American Banking and Market NewsCatheter Precision (VTAK) Set to Announce Quarterly Earnings on ThursdayCatheter Precision is expected to report quarterly earnings before market open on Thursday, November 12th. Analysts project a loss of $13.30 per share and revenue of $2.80 million. The company's stock opened at $0.15, with a market cap of $2.17 million.Third NewsFlyte Aviation's Strategic Shift: Selling Legacy Assets for Aviation ExpansionFlyte Aviation announced an LOI to divest its legacy cardiology subsidiary Catheter Precision and related product lines, aiming to focus solely on private aviation. The company reported 110% quarter-over-quarter revenue growth, with preliminary 2026 Q3 revenues near $2.1 million. Proceeds will fund fleet expansion and aircraft utilization improvements.Business & FinancialCatheter Precision Announces New FDA 510(K) Clearance For Its VIVO System, Enabling Use In A Broader Patient PopulationCatheter Precision received FDA 510(K) clearance for its VIVO system to use in patients with structural heart disease undergoing catheter ablation for monomorphic ventricular tachycardia. The company says clinical data shows the system maintains the same accuracy and safety as in patients without structural heart disease.Stock TitanCatheter Precision gets FDA 510(k) clearance for VIVOCatheter Precision announced FDA 510(k) clearance for expanded labeling of its VIVO system, now cleared for patients with structural heart disease undergoing catheter ablation for monomorphic ventricular tachycardia. The company says the expanded U.S. labeling is a milestone in delivering enhanced ablation strategies.TradingViewCatheter Precision Announces New FDA 510(k) Clearance for its VIVO System, Enabling Use in a Broader Patient PopulationCatheter Precision announced FDA 510(k) clearance for its VIVO system's expanded labeling, enabling use in patients with structural heart disease undergoing catheter ablation for monomorphic ventricular tachycardia. The company stated clinical data shows the system maintains the same accuracy and safety in these patients as in those without structural heart disease.Quiver QuantitativeCatheter Precision Reports LockeT Outperforms Perclose in First Published Comparative Study of Large Bore Venous Access Closure | VJET Stock NewsCatheter Precision published a study in The Journal of Interventional Cardiology comparing its LockeT device to Perclose after large bore venous access. The study of 172 patients found LockeT had a 1.2% complication rate versus 9.3% for Perclose, and zero device failures versus 4.7%. Both devices achieved similar hemostasis times and same-day discharge.FinancialContent Business PageCatheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure DeviceCatheter Precision published a 172-patient study comparing its LockeT suture retention device to Abbott's Perclose internal vascular closure device. LockeT reduced access-site complications to 1.2% versus 9.3% and achieved zero device failures versus 4.7%. The study was published in The Journal of Interventional Cardiology.TradingViewCatheter Precision (VTAK) Study Finds LockeT Outperforms PercloseCatheter Precision announced a 172-patient peer-reviewed study in JICE showing its LockeT suture retention device outperformed Abbott's Perclose in large-bore venous access for electrophysiologic procedures. The study reported fewer complications and zero device failures, with LockeT holding FDA Class I and CE Mark status.